UK MHRA pre-market requirements were published on May 8, 2026, for medical devices and in vitro diagnostic devices entering the Great Britain market. The draft Medical Devices (Amendment) Regulations 2026 are intended to improve patient safety, traceability, and access to innovative technologies.
The proposals remain in draft. Responses received during the comment period will inform the impact assessment and future implementation of the regulations.
UK MHRA Pre-Market Requirements: Key Proposals
- A new international reliance framework for certain devices already approved in Australia, Canada, or the United States
- Mandatory unique device identifiers
- Implant-card requirements
- IVD classification aligned with International Medical Device Regulators Forum principles
- Updated essential requirements and technical-documentation retention obligations
- New provisions for custom-made devices
- Alignment of manufacturer claims with the product’s stated intended purpose
What Manufacturers Should Consider
Organizations that maintain Great Britain device registrations or plan to enter the market should identify which proposed requirements could affect their products, documentation, labeling, traceability, and market-entry strategy. This review should include device classification, unique device identifiers, implant-card obligations, technical-documentation retention, custom-made device requirements, and permitted product claims.
Because the regulations remain in draft, companies should distinguish between current legal requirements and proposed future obligations while monitoring the implementation timetable and supporting guidance.
RJR Consulting can help organizations evaluate the UK MHRA pre-market requirements and prepare a proportionate Great Britain regulatory strategy. Start a conversation with RJR.
Source: MHRA announcement and Draft Medical Devices (Amendment) Regulations 2026.